SECURITIES AND EXCHANGE COMMISSION
                           Washington, D.C.  20549

                                 FORM 10-KSB

      [X]   ANNUAL REPORT  PURSUANT  TO  SECTION  13  OR  15(d)OF  THE
                       SECURITIES EXCHANGE ACT OF 1934

      [   ]  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)  OF THE
                       SECURITIES EXCHANGE ACT OF 1934

                For the fiscal year ended: December 31, 1999

                      Commission File Number: 000-25523

                         ANONYMOUS DATA CORPORATION
            (Exact name of registrant as specified in our charter)

Nevada                                                       86-0857752
(State or other jurisdiction of                            (I.R.S. Employer
incorporation or organization)                             Identification No.)

6170 W. Desert Inn
Las Vegas, Nevada                                          89146
(Address of principal executive offices)                  (Zip Code)

      Registrant's telephone number including area code: (702) 221-0756

         Securities registered pursuant to Section 12(b) of the Act:
                                    None

         Securities registered pursuant to Section 12(g) of the Act:
                       Common Stock, $0.001 par value
                              (Title of Class)

     Indicate by check mark whether the registrant (a) has filed all  reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934  during  the  preceding 12 months (or for such shorter period  that  the
registrant  was required to file such reports), and (2) has been  subject  to
such filing requirements for the past 90 days.  Yes    X      No  _____

     Indicate  by  check mark if disclosure of delinquent filers pursuant  to
Item  405  of  Regulation  S-K  is not contained  herein,  and  will  not  be
contained,  to  the  best of registrant's knowledge, in definitive  proxy  or
information statements incorporated by reference in Part III of this Form 10-
KSB or any amendment to this Form 10-K.  [     ]

     The  number of shares of Common Stock, $0.001 par value, outstanding  on
March   31,   2000,   was  11,530,660  shares,  held  by  approximately   113
stockholders.

<PAGE>

     This  form 10KSB contains forward-looking statements within the  meaning
of   the  federal  securities  laws.  These  forward-looking  statements  are
necessarily based on certain assumptions and are subject to significant risks
and uncertainties. These forward-looking statements are based on management's
expectations  as of the date hereof, and the Company does not  undertake  any
responsibility to update any of these statements in the future. Actual future
performance  and results could differ from that contained in or suggested  by
these  forward-looking statements as a result of factors set  forth  in  this
Form  10KSB  (including those sections hereof incorporated by reference  from
other filings with the Securities and Exchange Commission), in particular  as
set forth in "Business Risks" under Item 1 and set forth in the "Management's
Discussion and Analysis" under Item 6.

    In  this  form 10KSB references to "ADC" "we," "us," and "our"  refer  to
ANONYMOUS DATA CORPORATION.

PART I

ITEM 1.   BUSINESS

Overview

     Anonymous  Data  Corporation, a Nevada corporation  (the  "Company"  or
"ADC")  formed in November 1996, is a development stage company  engaged  in
the business of data management using a biometric identification system. The
biometric  identification  system; (i) archives  individual  data,  such  as
medical  educational  information, for access by  registered  users  through
rapid  sorting using scanning of a portion of their anatomy as a preliminary
search  method;  and,  (ii)  permits a second method  of  identification  of
individuals volunteering for payment as plasma donors.

Background

     We  have obtained rights to a method of linking files of archived  data
to the anatomy of an individual.  This method allows the search function for
records  to be more rapid and accurate and re-checked according to the  name
of  the  individual. We have spent $281,438 during 1999 toward research  and
development   toward  the  refinement  of  our  biometric  individual   data
identification system.

     The  term  BIOMETRIC derives from the words body (BIO) and  measurement
(METRIC).  The  science  of  biometrics has in recent  years  developed  the
technology  to  take a reading from a human (such as electronic  scan  of  a
fingerprint, iris scan, facial recognition, palm print, voice sample,  etc).
The  electronic  scan  is then matched with the same  biometric  marker  for
purposes  of  recognition and verification of identity.  The  United  States
Patent  and  Trademark Office has issued two U.S. patents to  Dr.  James  E.
Beecham, Chairman of the Company. The Patents, Patent Numbers U.S. 5,876,926
[PCT/U.S.  98/16435]) and U.S. 5,897,989 [PCT/U.S. 97/08015], pertain  to  a
method,  system  and apparatus that permit an individual to submit  biologic
test  specimens  for  medical  testing under biometric  identification.  The
system  then  allows  for the subsequent retrieval of test  results  from  a
computerized  database utilizing the same biometric personal identification.
These  Patents have been exclusively licensed to us from Dr. Beecham. -  See
"Certain Transactions - License Agreement."

     The  patented applications, in non-U.S. territories, will  be  utilized
for collecting medical specimens in containers labeled by "biometric index".
For  example,  a  biometric  index  may be  obtained  from  the  scan  of  a
fingerprint  and/or the scan of the iris of the eye of the  specimen  donor.
After   testing  in  a  certified  laboratory,  the  test  data  is   stored
electronically under linkage to that same personal biometric  index.  Access
to  such "biometrically" stored information is controlled by the re-scan  of
the specimen donor. Since viewing the data requires "unlocking" the computer
file by scanning the same fingerprint and/or eye as was used for sending the
specimen  to  the  lab  in the first place, our system provides  the  secure
protection of the donors sample and limits mistakes that are sometimes  made
in the donation process.

<PAGE>

     We  have developed a plan and are in the process of developing a method
for  providing services and products worldwide based on our exclusive patent
licenses.  We plan to offer these products as turnkey systems  and  also  to
offer services directly to subscribers domestically and abroad.

Current Status of ADC's Products and Related Software

     ADCNET, a comprehensive software and hardware system, was designed to be
generic to support all four of the current ADC product line. Namely, 1) Court
Mandated  Data  System,  2) Infectious Disease Education  System,  3)  Plasma
Industry  System,  and  4)  Medical Records  Privacy/Genetics  Data  Security
System.

     Each  of the four products named above requires a shared database  in  a
Local   Area  Network  (LAN)  or  a  Wide  Area  Network  (WAN)  environment.
Functionally, each of the systems has an "Enroll," "Recognize," "Print2D  bar
code control label," and "Enter Results" options.

     Two  versions of ADCNET are planned: Version .5 and Version 1.0. Version
 .5  is currently beta testing as a "Pilot Court Data System" for the American
Toxicology  Institute,  and Las Vegas Family Court. This  Version  is  a  LAN
between  the  Court and the Drug Testing Lab. Both sites are  anticipated  to
share  a database located at the Court. Version 1.0 will permit each location
to  continue processing in the event of a power failure, until such  time  as
the  power is restored, at which time the database is automatically  updated.
Version 1.0 is scheduled to be completed in late September, 1999.

     The Prototype ADCNET Version .5 is currently installed as a beta testing
system  at the American Toxicology Institute and the Las Vegas Family  Court.
This  system is operational and is anticipated to be evaluated by both  Court
and  Lab  personnel.  Minor enhancements are being noted  as  the  system  is
commissioned and these enhancements will be implemented in Version 1.0.

     To  become market ready, Version 1.0 will require customer modifications
specific to each customer. Modifications such as Title Screen, Customer name,
Customer  Address,  etc.,  will  have to  be  programmed  for  each  Customer
Installation.

     The  completion and operational status of the four systems as described
below,  utilizing ADCNET, will be developed through manufacturing contracts,
corporate  strategic partnerships and sublicense agreements  with  U.S.  and
foreign governments, corporations and other organizations.

     * Court  Information System. Developed for the benefit of United  States
       judicial  order  compliance. The system pre-identifies  an  individual
       whom  the  court orders to proceed to the laboratory for drug testing.
       The  laboratory, prior to the standard identification process such  as
       by  drivers  license verification, rechecks the identity by  biometric
       index.  This double check is independent of all laboratory  procedures
       and  does not interface or replace the methods and systems within  the
       laboratory.

     * Infectious  Disease Educational System. Developed for individuals  and
       social  organizations in the United States interested in  communicable
       disease  prevention through voluntary testing and sharing  of  results
       privately  with  selected persons among the public. A study  published
       in   1998   in   the  Journal  of  the  American  Medical  Association
       demonstrated the important contribution of education and anonymity  in
       the  U.S.  for HIV testing. The study concluded that when  people  are
       aware  of  the  disease and not required to give their  name  but  are
       offered anonymous HIV testing, they voluntarily test more than 1  year
       earlier  and  enter  medical care earlier. Most U.S.  states  are  now
       required to permit anonymous HIV testing.

   *    In the foreign markets we plan to offer turnkey computerized systems for
    nationwide medical testing and data management.  One use would be by foreign
    government officials to monitor child bearing age women and their HIV test
    results. By re-scanning their biometric index when they arrive at  the
    maternity ward to deliver, HIV positive women can be given AZT, which in 80%
    of cases protects their baby from HIV infection.

<PAGE>

     * Plasma  Industry System. Developed for use in U.S. plasma  centers  to
       prevent  the  paid  donor  from  violating  regulations  that   forbid
       donation  more frequently than 48 hours. By registering the  biometric
       index  of  the  donor in one center and providing the  data  to  other
       centers,  a  paid  donor, even giving a false name, can  be  prevented
       from  creating  the health risk of donating plasma for  money  several
       times in one day at multiple centers in one city.

     * Medical  Data  Privacy/Genetics Data Security  System.  Developed  for
       U.S.   health   care  organizations  and  individuals  interested   in
       verifying  and safeguarding their sensitive medical testing data  such
       as  genetic testing results.  In particular where such genetic studies
       identify  predisposition to disease or can predict future disease  and
       thus  if disclosed to unauthorized parties affect insurability of  the
       individual tested and their family. Developed to allow those who  wish
       to   seek  testing  directly  from  a  laboratory  to  identify  their
       specimens and test results while maintaining privacy.

     The  primary  product  lines listed above each  utilize  a  proprietary
apparatus  as  disclosed in the licensed patents to  be  used  in  archiving
medical   information   for  educational  purposes.   Data   retrieval   via
computerized stored data or from a 2-D bar code encryption is  linked  to  a
re-scanning of the donor for matching biometric identification.

     The Company's technology may be utilized in the marketplace for revenue
generation in two areas:

(i)  as a seller of hardware components and software for turn-key systems for
     large clients and;

(ii) as a provider of services to subscribers directly in certain localities.

The systems which ADC plans to offer for these 2 business models are:

Court Data System

     As  a  direct service provider, we are beta testing a prototype  system
code  named, "ADCNET," which utilizes biometric identification in the Nevada
court jurisdiction. ADCNET is designed to be utilized by the judicial system
to verify the identification of an individual ordered by the judge to report
to the laboratory for drug testing. The system matches the identification of
the individual biometricly by matching his/her biometric identification with
the  biometric image of the individual who has been ordered by the judge for
testing.  We are not involved in the testing or laboratory work  up  itself,
merely the means by which the test results are confirmed as having come from
the person identified. The standard laboratory procedures are still followed
independently of the biometric system. The affiliated laboratories are fully
inspected and in compliance with all governmental regulation such  as  CLIA,
OSHA, etc.

Infectious Disease Education System

     We  have  designed  a direct service data management system,  that  can
allow  thoughtful  persons seeking information and a  way  to  address,  for
themselves   and   their  loved  ones,  personal  issues  regarding   health
information. Understanding how the system works requires an understanding of
the  value of information that can allow a person to assess the risk of  the
spread of disease when engaged in a relationship. The basic question is "How
and when are these diseases usually transmitted?"

<PAGE>


     Sexually  transmitted  diseases  are ordinarily  transmitted  from  one
person  to another, not from a single sexual contact, but rather only  after
repeated contacts over weeks or even months. Thus, even after a relationship
starts,  there  is  an opportunity to prevent the spread of  disease,  if  a
person  has  the  knowledge  of the partners' recent  testing  results.  Our
technology provides that information in a convenient and private manner.

     To  use the system as a tested person, you (i) first subscribe yourself
as  an  individual, (ii) select from a menu of educational data offered  and
then (iii) register as having read the data and understood the process.  For
convenience, our system is planned to be utilized as a college campus health
service  or  private  community health service located  in  storefront  type
clinics  in  public  places. Our system is planned  to  allow  a  parent  to
subscribe for an adolescent child. Over the next months or years, the parent
will be able to monitor the compliance of the child to our education program
by  going with the child to a computer monitor, having the adolescent childs
fingerprint  scanned or iris scanned and viewing the record  of  educational
sessions with the adolescent child.

     In the international market, in circumstances where a sex worker is the
subscribed person (through government mandate in certain jurisdictions)  the
authorities can scan the iris of the sex worker's eye and view that worker's
data from the database, which database includes HIV test results. Where  the
worker  has  not  continued to be tested periodically  the  authorities  can
arrest or detain the non-compliant worker. Similarly in circumstances  where
the  authorities provide the system for use of child-bearing age  women  the
system can be used to identify those pregnant woman who are HIV positive. By
providing  AZT  to an HIV positive woman during delivery, the newborn  child
can  be  protected  from  HIV  80% of the time. In  addition,  for  overseas
markets,  in  compliance  with  the foreign government  regulations,  it  is
important  that  the subscriber and the significant other in a  relationship
understand our rules for data retention. Our data base management techniques
enhance  the  medical  validity of data in the Golden  Rule  database.  Each
subscriber,  in  order to maintain data in the active Golden Rule  database,
may  be  required  to present a specimen to be tested at  least  every  four
months.  If  a  recent specimen is not provided at one of the participating,
certified laboratories in our system, no older data is accessible.

     Internationally,  this testing frequency is designed  to  be  medically
appropriate because in most cases it takes six weeks to several  months  for
an  immuno-competent, recently infected person to make enough antibody to be
detectable. (Some newer tests utilize antigen identification, not  antibody,
i.e.  a  substance such as nucleic acid -DNA or RNA or cell  wall  fragments
from  the organism itself, to detect infection sooner. These viral bacterial
antigen  detection  tests  may  be applied in  the  Golden  Rule  system  as
appropriate).  The person with whom the data is shared can  have  confidence
that  the  data is valid at least as of the most recent date tested  because
they  will  know  that  the Golden Rule system imposes  a  frequent  testing
discipline on the subscriber with medical officer review and comment on test
results.

     In  the international area, the seven diseases for which testing can be
ordered  by  a  physician and data sharing are targeted by our  Golden  Rule
System  are:  Human  Immunodeficiency Virus or  HIV;  Gonorrhea;  Chlamydia;
Herpes type 2; hepatitis B and C; and Syphilis.

     We  have demonstrated the system for representatives of the Governments
of  Honduras  and  the Dominican Republic. Similarly the  national  turn-key
system  will be available at the option of the client government to  locate,
in public places such as hotel lobbies and selected nightclubs, customers of
sex  workers  in order to verify the test results of the sex worker  in  the
field on a 24 hour per day access basis.

      ADC  plans to offer to the government of those countries identified  as
having a major HIV/AIDS problem the ADCNET solution. The initial countries to
be  approached are identified in the U.S. Census Bureau, Official Statistics,
2/2/99  and  the  World Bank Study of Central America to  include:  Honduras,
Nicaragua,  Panama,  Costa Rica, El Salvador, Dominican Republic,  and  other
Caribbean  countries.  In the year 2,000 and beyond ADC plans to  expand  its
list of High-Risk countries for marketing.

<PAGE>
Plasma Industry System

     In  the plasma industry paid donors often falsify their name and try to
donate  at  several  centers  in  one day to  gain  multiple  payments.  Our
DataSecure system offers a means to improve the chances that the  high  risk
donors  or  donors attempting to circumvent the system by donating  multiple
times  prior to the wait period, are accurately linked to the plasma  center
computer database and, optionally, remain confidential.

     The  DataSecure system for plasma centers permits biometric linkage  to
be  maintained  from  start  to  finish in a two-step  process:  a)  through
biometric  label of iris of the prospective donor, and b) in the network  of
computers to other blood centers.

     An  alternative  use of our turnkey system is for  use  in  the  plasma
industry  to  screen out donors who carry infections. The DataSecure  system
for  the plasma industry permits biometric linkage to be maintained for paid
donors to records of their previous donations and testing results. When  one
donor  tests positive for a condition disqualifying that donor from donating
plasma,  the information is entered under the biometric of that donor.  When
that  donor next appears at any blood donation site in the computer network,
the  re-scan  of  the biometric accesses the record and  enables  the  blood
center  personnel  to disqualify that donor. This step prevents  unnecessary
expense  in  re-testing  and  more importantly allows  a  subscribing  blood
industry  company to prevent inadvertently drawing the blood of that  donor,
who  may  attempt  to  falsify identity to gain payment  for  tainted  blood
donation.

Medical Records Privacy/Genetics Data Security System.

     Medical records privacy has become a prominent concern of U.S. national
leaders,  as demonstrated by President Clinton in his January 1999 State  of
the  Union  address in which he promised action on this issue in 1999.  Many
sensitive  medical data are at issue including testing data,  in  particular
the  area  of genetic testing. Scientists today are close to completing  the
sequencing of all of the human DNA code through an effort known as the Human
Genome  project.  One early finding is rather surprising.  Each  of  us  has
little  imperfections in our own DNA code. In fact, experts say each  of  us
has a minimum of 5 to 20 errors in our DNA sequence.

     Some of these errors result in disease or, more precisely, an increased
risk of developing a certain disease. For example, there are genes now known
that  predispose  to breast cancer, colon cancer, diseases  of  the  nervous
system and over 450 other different diseases. Tests for many of these  genes
are either available now or soon to be available.

     Unfortunately  information of this type, if  released  to  unauthorized
persons,  may lead to discrimination. Some unscrupulous health insurers  may
use genetic test information to deny insurance to those persons found to  be
at  risk for certain diseases. Although Congress and some medically oriented
government  agencies are drafting legislation to outlaw such discrimination,
it is one form of discrimination that is difficult to detect or prove.

     Our  data  base  of  Private Medical test results  and  Genetic  Testing
results  is planned to be filed in a unique manner, by fingerprint  codes  or
iris codes: the fingerprint scan or iris scan of the person who is tested for
genetic markers (the ADC subscriber) and optionally a second fingerprint code
or  iris  code from the subscriber's doctor. This dual biometric  filing  and
retrieval method for genetic testing data offers a subscriber confidence that
sensitive  test  results such as genetic predisposition to diseases  such  as
breast cancer (BRCA-1 gene) or colon cancer or diabetes are not accessible by
unauthorized individuals or organizations. Furthermore, the fingerprint  scan
or  iris  code  module  having  a  clinic setting  presents  the  appropriate
opportunity for genetic counseling and for education by the physician to  the
subscriber privately of the meaning of the results. This allows plans  to  be
made  for  medical surveillance for the disease for which the patient  has  a
genetic predisposition.

<PAGE>

Business Strategy

     Our  business  strategy is to make proposals to interested governments,
large  corporations and interest groups domestically and overseas. As vendor
of  hardware  and  software turnkey systems for large clients,  the  Company
plans  to  approach those countries where the problems exist for  which  the
systems  offer  solutions.  In  order to  provide  services  to  subscribers
directly, the Company plans to research the medical and legal aspects of its
proposed services in each jurisdiction through appropriate consultation with
local officials.

     We  hope  to expand the system within the U.S. market and abroad through
contracts   with   medical   service  providers,  insurance   companies   and
laboratories.

Product Testing

     The  testing phase for each of the two systems will occur with  funding
of pilot projects, when such funding is available.

     FDA REGULATIONS SPECIFY THAT PRODUCTS AND SOFTWARE USED FOR EDUCATIONAL
PURPOSES ONLY ARE EXEMPT FROM FDA REGULATION. FURTHERMORE PRODUCTS  THAT  DO
NOT  PROVIDE DIAGNOSIS OR TREATMENT ARE EXEMPT AND NOT CONSIDERED A  MEDICAL
DEVICE.   The  initial four product lines qualify for the exemptions  stated
above.  Future development of U.S. market products in line with  the  issued
patents and related software programming domestically will take note of  FDA
regulations in anticipation of submitting applications for approval  to  the
FDA  as  necessary. We have also engaged the services of C. L. McIntosh  and
Associates,  a  prominent  consulting firm in the  area  of  FDA  regulatory
matters, to assist us in any future FDA related matters. Field-testing  will
occur  in  the  venue best suited to each system, whether  in  the  U.S.  or
abroad.

Suppliers

     Our  business  strategy has been to combine proprietary  technology  and
products  with  "best  of  class"  technology  and  products  and  design  an
integrated, seamless product that takes advantage of the superior quality  of
our components which are Y2K compliant.

     Hardware Suppliers- Our products and services are not dependent on  any
one  supplier  of  hardware  and will use any off-the-shelf  IBM  compatible
computer available on the market today, i.e.-Compaq, DELL, Gateway, etc.  We
do  not  foresee the acquisition of such equipment as a problem  and  supply
should not affect our business in any way.

     We use cameras designed by IriScan in the majority of our applications,
however,  there are several other companies that make similar cameras,  such
as  OKI  corporation of Japan. Fingerprint scanners produced  by  UltraScan,
Inc. are also under consideration.

Software Suppliers

     We primarily use software based on Oracle database products designed by
Dimensia Inc. of Hawaii.

Sales and Marketing

      Initially,  the  Company,  through its  officers,  directors  and  key
consultants,  plans  to  start  pilot programs  in  strategic  markets  with
corporate  partners such as Toyota Tsusho and Litton Data Systems  and  upon
the  success of these programs, plans will be to set up Strategic  Alliances
with  these  and other highly visible and well known vendors throughout  the
world.

<PAGE>

Strategic Alliances

     Our  success  will  be  dependent in part upon  a  number  of  strategic
relationships  that  we  intend  to enter  into.  At  present,  we  have  not
established  relationships with any particular entity,  however,  we  are  in
discussions  with  several large companies, both locally and internationally.
The amount and timing of resources which future strategic partners devote  to
assisting  us will not be within our control. There can be no assurance  that
strategic  partners will perform their obligations as expected  or  that  any
revenue  will be derived from strategic arrangements. If any of our strategic
partners  breaches or terminates an agreement with us or otherwise  fails  to
conduct  its  collaborative activities in a timely manner,  the  development,
commercialization  or marketing of the product which is the  subject  of  the
agreement  may  be  delayed and we may be required  to  undertake  unforeseen
additional responsibilities or to devote additional resources to development,
commercialization or marketing of our products.

   The  inability to enter into strategic relationships or the failure  of  a
strategic  partner to perform its obligations could have a  material  adverse
effect on our business, financial condition and results of operations.  There
can  be  no  assurance that we will be able to negotiate acceptable strategic
agreements in the future, that the resulting relationships will be successful
or that we will continue to maintain or develop strategic relationships or to
replace   strategic  partners  in  the  event  any  such  relationships   are
terminated.  Our  failure  to  maintain  any  strategic  relationship   could
materially and adversely affect our business, financial condition and results
of operations. We are currently in negotiations with IriScan and UltraScan to
determine  the terms under which we have access to their respective biometric
technology.

Customer Support

     In  addition  to  ongoing client prospecting and product demonstrations
through direct sales, a satisfied customer is one of the most cost-effective
sales  tools  for  our systems is a satisfied customer. Our  customers  will
generally  require  significant support and training  with  respect  to  our
products,  particularly in the initial deployment and implementation  stage.
We  intend  to  provide  support via telephone,  teleconference  or  on-site
visits,  and anticipate hiring additional staff as our customer base  grows.
Next  to  product  quality and ease of use, we will  always  place  customer
satisfaction  and  technical  support as its highest  marketing  priorities.
However,  we have limited experience with widespread deployment of  products
to  a diverse customer base, and there can be no assurance that we will have
adequate  personnel to provide the levels of support that our customers  may
require  during  initial  product deployment or  on  an  ongoing  basis.  An
inability  to  provide sufficient support to our customers  could  delay  or
prevent  the  successful  deployment of our  products.  Failure  to  provide
adequate  support  could  have  an adverse  impact  on  our  reputation  and
relationship with its customers, could prevent us from gaining new customers
and  could  have  a  material  adverse effect  on  our  business,  financial
condition or results of operations.

Competition

     We  compete  indirectly with certain companies which utilize biometrics
in related fields, such as Sony Corporation and Lockheed Martin Corporation,
which  have  biometric systems on the market that are in current use.  Other
companies,   such   as   NEC   Technologies,  have   biometric   fingerprint
identification  systems  on  the  market for physician  identification  when
accessing  computerized patient information rather than a  specific  patient
file.  IriScan  Inc.  may  elect  to  retain  the  right  to  offer  IriScan
recognition systems in the medical field either directly or through  vendors
other than to us who then may compete with us.

      We  are  aware of medical data collection, storage and display systems
technology   entitled'  "Medical  Image  Filing  Apparatus,"   and   "Health
Examination Method and System Using Plural Self-Test Stations and a Magnetic
Card."  These  systems store medical data on magnetic media contained  on  a
card or film.

      Because  we  are  not  a testing laboratory we  do  not  compete  with
laboratory companies.

<PAGE>

Developing and Changing Market

     The  market  for  archiving  of medical data management  is  continually
evolving  and  is  highly  dependent upon changes in  the  regulation  arena.
Concern for privacy appears to be a favorable development for us. Changes  in
technology  and  regulatory processes, however, may  affect  the  demand  our
products,  which in turn may cause existing companies in other product  lines
to  shift  their emphasis to products similar to our services  and  products,
thus increasing the competition.

Intellectual Property

     Two  U.S.  patents  are  currently licensed  exclusively  to  us  (U.S.
5,876,926  [PCT/  US98/16435]  and 5, 897, 989  [PCT/US97/08015])  from  our
Chairman, James E. Beecham, MD. The Exclusive Licensee Territorial Agreement
is  for the territory of the United States with provisions for expansion  of
the  licensed  territory  on a 1st right basis under  terms  and  conditions
relating  to  payment  of  patent fees, use of the license  and  payment  of
royalties.  These U.S. licenses are exclusive and non-revocable for the term
until  May  14,  2008  assuming compliance of the parties  with  the  terms.
Pursuant to the License Agreement, a fee will be paid to Dr. Beecham in  the
form  of  a  royalty  of three percent (3%) of the first $10  million  gross
revenues  to us from the manufacture, use, sale or operation of the Products
and  Services, two percent (2%) of gross revenues which exceed  $10  million
but  are less than $25 million and one percent (1%) of gross revenues  which
exceed  $25  million.  Dr.  Beecham has also agreed  to  extend  the  patent
licenses for us for these two U.S. patents for an additional eight (8) years
depending on performance.  We consider these licensed patents to be valuable
and of substantial commercial benefit.

     We  also  seek to protect our intellectual property rights by  limiting
access  to  the  distribution  of  our  software,  documentation  and  other
proprietary   information.  In  addition,  we  enter  into   confidentiality
agreements  with our employees and certain customers, vendors and  strategic
partners.  There  can be no assurance that the steps taken  by  us  in  this
regard  will  be adequate to prevent misappropriation of our  technology  or
that  our  competitors will not independently develop technologies that  are
substantially equivalent or superior to our technologies.

     By  virtue  of his agreement with us, Dr. Beecham is under no obligation
to  assign or license to us any additional patents he may receive beyond  the
initial  two U.S. patents already licensed by us. A first rights  of  license
provision  for  additional patents by Dr. Beecham  in  the  area  of  medical
biometrics  is  in  place in exchange for our promise  to  provide  funds  to
underwrite the costs of additional patent filings and prosecution.  There can
be  no assurance that any patents, federal trademarks or services marks  will
be granted, additional patents will be licensed or that the licensed patents,
although issued by the Patent and Trademark Office, can be defended  or  will
permit substantial protection for our services or products.

U.S. Government Approvals

     The United States Food and Drug Administration (the "FDA"), is the most
stringent  regulatory agency for medical devices and  claims  and  may  have
jurisdiction  over  one  or more of our services and  products.   Exemptions
exist for non-diagnostic and non-treatment data archiving system.  We expect
that   biometric-based  information  systems  that  provide  archival   non-
diagnostic,  non-treatment data, will be exempt. However, there  can  be  no
guarantee  that the governmental regulations will not change in the  future.
Governmental  guidelines for universal and special precautions for  handling
infectious  disease  material do not apply to us  since  we  are  a  medical
education  and  data storage, retrieval and dissemination service.   Neither
can  there  be  a  guarantee that our products or services can  successfully
compete with those of other competitors, or that the protection provided  by
the U.S. patents licensed by us will be successful in preventing competitors
from  offering  services or products similar ours. We further  believe  that
certain  of our products and services may not qualify for exemption  without
FDA  pre-market approval. FDA approval should be expedited by our  plans  to
utilize consultants familiar with FDA procedures. There can be no guarantee,
however, that these approvals will be received in an expeditious manner. The
overseas markets vary in regulatory oversight country by country.

<PAGE>

Foreign Government Approvals

      The  Company  and  its  products may be subject to  foreign  regulation
regarding  export  restrictions  and controls  on  technology  such  as  that
incorporated  into the Company's products. Additional approvals from  foreign
regulatory  authorities may be required, and there can be no  assurance  that
the Company will be able to obtain foreign approvals on a timely basis or  at
all,  or that it will not be required to incur significant costs in obtaining
or  maintaining its foreign regulatory approvals. In Europe, the Company will
be  required to obtain certifications necessary to enable the "CE" mark to be
affixed to the Company's products in member countries of the European  Union.
The  CE  mark  is  an  international symbol  of  quality  and  complies  with
applicable  European  medical device directives.  The  Company  has  not  yet
obtained  this  CE  certification. Failure to comply with foreign  regulatory
requirements could have a material adverse effect on the Company's  business,
financial  condition and results of operations. In addition,  the  increasing
demand  for  biometric  systems  has exerted pressure  on  regulatory  bodies
worldwide  to  adopt new standards for such products and services,  generally
following   extensive  investigation  of  and  deliberation  over   competing
technologies. The delays inherent in this governmental approval  process  may
cause  the cancellation, postponement or rescheduling of the installation  of
systems by the Company's customers, which in turn may have a material adverse
effect on the sale of products by the Company to such customers.

      Many countries in which the Company currently intends to operate either
do  not  currently regulate devices similar to the Company's or have  minimal
registration   requirements;  however,  these  countries  may  develop   more
extensive regulations in the future that could adversely affect the Company's
ability  to  market its products in such countries. In addition,  significant
costs   and  requests  by  regulators  for  additional  information  may   be
encountered by the Company in its efforts to obtain regulatory approvals. Any
of  such  events  could  substantially delay or  preclude  the  Company  from
marketing its products in the U.S. or internationally. Failure to comply with
applicable regulatory requirements can result in loss of previously  received
approvals and other sanctions and could have a material adverse effect on the
Company's business, prospects, financial condition and results of operations.

     Additionally,  the Company and its agents will be subject to  compliance
with  the  Foreign Corrupt Practices Act of 1977, as amended ("FCPA"),  which
prohibits  the promise or payments of any money, remuneration or other  items
of  value  to  foreign government officials, public office holder,  political
parties  and  others  with regard to the obtaining or  preserving  commercial
contracts  or  orders.  The FCPA imposes on SEC reporting  companies  certain
accounting and internal control requirements, with which the Company  intends
to  comply, insofar as applicable to the Company. Violation of the  FCPA  may
result  in  corporate fines of up to $1,000,000 per offense and fines  and/or
imprisonment for convicted corporate officers of up to $10,000 and five years
imprisonment. Although the Company will make every effort to comply with  all
such  statutes  and regulations, inadvertent non-compliance could  result  in
legal actions against the Company and consequent impairment of its ability to
conduct  business  and  these restrictions may  hamper  the  Company  in  its
marketing efforts abroad.

Risks Associated with International Sales

      A  number  of  risks  are  inherent  in  international  operations  and
transactions. International sales and operations may be limited or  disrupted
by  the  imposition  of  government controls,  export  license  requirements,
political   instability,   trade  restrictions,  changes   in   tariffs   and
difficulties in staffing, coordinating and managing international operations.
Additionally, our business, financial condition and results of operations may
be  adversely  affected  by fluctuations in international  currency  exchange
rates  as well as constraints on our ability to maintain or increase  prices.
The international nature of our business subjects us and our representatives,

<PAGE>

agents  and distributors to laws and regulations of the foreign jurisdictions
in  which  they operate or in which our products are sold. The regulation  of
medical  devices  in  a  number of such jurisdictions,  particularly  in  the
European  Economic Area, continues to develop and there can be  no  assurance
that  new  laws or regulations, or new interpretations of existing  laws  and
regulations,  will  not  have  a material adverse  effect  on  our  business,
prospects,  financial condition and results of operations. In  addition,  the
laws  of  certain foreign countries do not protect our intellectual  property
rights  to  the  same  extent as do the laws of the  U.S.  There  can  be  no
assurance  that  we  will be able to successfully further  commercialize  our
current  products or successfully commercialize any future  products  in  any
international market.

Risks Associated with Acquisitions

      The integration of any acquisitions will require special attention from
management, which may temporarily distract its attention from the  day-to-day
business  of  the Company. Any acquisitions will also require integration  of
the  Company's product offerings and coordination of research and development
and sales and marketing activities. Furthermore, as a result of acquisitions,
the  Company  may  enter markets in which it has no or  little  direct  prior
experience. There can also be no assurance that the Company will be  able  to
retain  key  technical  personnel  of an  acquired  company  or  recruit  new
management  personnel for the acquired businesses, or that the Company  will,
or  may in the future, realize any benefits as a result of such acquisitions.
Acquisitions  by the Company may result in potentially dilutive issuances  of
equity  securities, the incurrence of debt, one-time acquisition charges  and
amortization  expenses  related to goodwill and intangible  assets,  each  of
which  could  be  significant  and  could  materially  adversely  affect  the
Company's  financial condition and results of operations.  In  addition,  the
Company  believes that it may be required to expand and enhance its financial
and  management controls, reporting systems and procedures as  it  integrates
acquisitions. There can be no assurance that the Company will be able  to  do
so  effectively,  and failure to do so when necessary would have  a  material
adverse  effect upon the Company's business, financial condition and  results
of operations.

Employees

      As  of  December 31, 1999, we had 4 full time employees. All employees
are  located  at  our headquarters in Las Vegas. None of our  employees  are
subject to any collective bargaining agreement.

      Our  proposed  personnel  structure can be  divided  into  three  broad
categories:   management  and  professional,  administrative,   and   project
personnel.  As  in  most small companies, the divisions between  these  three
categories  are  somewhat indistinct, as employees  are  engaged  in  various
functions as projects and work load demands.

     We are dependent upon the services of James E. Beecham, MD, Chairman of
the  Company and President.  Our future success also depends on our  ability
to  attract  and retain other qualified personnel, for which competition  is
intense.  The  loss  of Dr. Beecham or our inability to attract  and  retain
other qualified employees, could have a material adverse effect on us.

Additional Information

     We  are  subject  to  the informational requirements of  the  Securities
Exchange Act of 1934 (the "Exchange Act") and, in accordance therewith,  will
file  reports,  proxy statements and other information with  the  Commission.
Such  reports,  proxy statements and other information may  be  inspected  at
public  reference facilities of the Commission at Judiciary Plaza, 450  Fifth
Street N.W., Washington D.C. 20549; Northwest Atrium Center, 500 West Madison
Street, Suite 1400, Chicago, Illinois 60661; 7 World Trade Center, New  York,
New  York, 10048; and 5670 Wilshire Boulevard, Los Angeles, California 90036.
Copies of such material can be obtained from the Public Reference Section  of
the  Commission  at Judiciary Plaza, 450 Fifth Street N.W., Washington,  D.C.
20549  at  prescribed  rates. For further information, the  SEC  maintains  a
website  that contains reports, proxy and information statements,  and  other
information   regarding  reporting  companies  at  (http://www.sec.gov).   We
maintain a website at www.adcx.com.

<PAGE>

Risks Associated with Year 2000 Problem

     We have had no noticeable impact as the result of the year 2000 problem.
As is the case with most other Companies using computers in their operations,
we  recognize  the need to ensure that our operations will not  be  adversely
impacted  by  software and/or system failures related  to  such  "Year  2000"
noncompliance.  Within  the  past  twelve  months,  we  have  been  upgrading
components  of  our  own  internal  computer  and  related  information   and
operational  systems  and  continue to assess the  need  for  further  system
redesign  and believe it is taking the appropriate steps to ensure Year  2000
compliance.  Based on information currently available, we believes  that  the
costs  associated  with  Year  2000  compliance,  and  the  consequences   of
incomplete or untimely resolution of the Year 2000 problem, will not  have  a
material  adverse effect on our business, financial condition and results  of
operations in any given year. However, even if our internal systems  are  not
materially  affected  by  the  Year  2000 problem,  our  business,  financial
condition  and  result of operations could be materially  adversely  affected
through  disruption  in  the  operation of  the  enterprises  with  which  we
interact.  There can be no assurance that third party computer products  used
by  us  are  Year  2000 compliant. Further, even though we believe  that  our
current  products  are Year 2000 compliant, there can be  no  assurance  that
under actual conditions such products will perform as expected or that future
products will be Year 2000 compliant.

     Since  we  have not commenced substantial operations, third parties  non
compliance  with the Year 2000 issue will have minimal impact on  us.  We  in
contracting  with  new vendors, manufactures, and plants are pre-establishing
the third party's compliance with Year 2000 issues.

ITEM 2.   PROPERTIES

     The Company's main offices are located at 6170 W. Desert Inn, Las Vegas,
Nevada. The facility is a leased 1,500 square foot facility utilized  in  the
following  manner:  a)  administrative offices, b) professional  offices,  c)
storage, and d) developmental laboratory. These headquarters are adequate for
marketing  throughout  the  United States. The  Company  anticipates  it  may
require  additional  space in the future, but anticipates  no  difficulty  in
obtaining  such  space  in  its immediate vicinity at  favorable  rates.  The
Company  pays  rent  at the rate of $3,000 per month. The Company  has  other
tangible  property,  including computer equipment, proprietary  software  and
biometric prototype.

ITEM 3.   LEGAL PROCEEDINGS

     The  Company recently settled a suit filed on January 14, 2000  by  Asia
Pacific,  Inc., a Nevada Corporation, dba Laser Barcode Solutions, which  was
filed  in  District  Court  in  Clark County,  Nevada,  Case  Number  A413603
Department  XII  against Anonymous Data Corporation and the  President  James
Beecham  claiming  Breach  of  Contract,  Tortious  Breach  of  Contract  and
Negligent/Intentional Misrepresentation.

ITEM 4.   SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

     No  matter  was  submitted to a vote of security  holders,  through  the
solicitation of proxies or otherwise, during the fourth quarter of our fiscal
year ended December 31, 1999.

<PAGE>

PART II

ITEM 5.   MARKET  FOR  REGISTRANT'S  COMMON EQUITY  AND  RELATED  STOCKHOLDER
          MATTERS

     Our  Common  Stock  is traded in the over-the-counter securities  market
through  the  National Association of Securities Dealers Automated  Quotation
Bulletin  Board  System, under the symbol "ANYD".  The following  table  sets
forth  the quarterly high and low bid prices for our Common Stock as reported
by  the  National  Quotations Bureau.   The quotations  reflect  inter-dealer
prices,  without  retail  mark-up,  markdown  or  commission,  and  may   not
necessarily represent actual transactions.
<TABLE>
                                     1999
                    Average Bid           Average Ask
<S>                <C>                    <C>
     November       $2.09                    $2.64
     December       $1.87                    $2.14
</TABLE>

Note: We started trading in November, 1999

     As  of  March  31,  2000, we had approximately 113 stockholders  of  the
11,530,660 shares outstanding.

     We have never declared or paid dividends on our Common Stock.  We intend
to  follow  a policy of retaining earnings, if any, to finance the growth  of
the  business  and  do  not  anticipate paying  any  cash  dividends  in  the
foreseeable future.  The declaration and payment of future dividends  on  the
Common  Stock will be the sole discretion of the Board of Directors and  will
depend  on  our  profitability and financial condition, capital requirements,
statutory  and  contractual restrictions, future prospects and other  factors
deemed relevant.

ITEM 6.   MANAGEMENT'S  DISCUSSION  AND ANALYSIS OF FINANCIAL  CONDITION  AND
          RESULTS OF OPERATIONS

     The following discussion and analysis should be read in conjunction with
our  Financial Statements and the notes thereto appearing elsewhere  in  this
document.

RISK FACTORS AND CAUTIONARY STATEMENTS

      This  report contains forward-looking statements within the meaning  of
Section  27A of the Securities Act of 1933 and Section 21E of the  Securities
Exchange Act of 1934. Actual results and events could differ materially  from
those  projected, anticipated, or implicit, in the forward-looking statements
as a result of the risk factors set forth below and elsewhere in this report.

      With  the exception of historical matters, the matters discussed herein
are  forward looking statements that involve risks and uncertainties. Forward
looking  statements  include, but are not limited to,  statements  concerning
anticipated  trends in revenues and net income, the date of  introduction  or
completion  of our products, projections concerning operations and  available
cash  flow.  Our  actual  results could differ materially  from  the  results
discussed in such forward-looking statements. The following discussion of our
financial  condition and results of operations should be read in  conjunction
with  our  financial  statements  and the  related  notes  thereto  appearing
elsewhere herein.

Overview

     The  Company,  which was organized in November 1996, is  a  Development
Stage Enterprise, engaged in the business of marketing services and products
related   to   the   management  of  data  based  on  biometric   individual
identification.  The  Company has a limited operating history  and  has  not
generated  revenues  from  the sale of any products.  The  Company  recently
installed  its beta testing system at the American Toxicology Institute  and
in  the Las Vegas Family Courts. Until the installation of the system in Las

<PAGE>

Vegas,  the  Company's activities have been limited to  the  development  of
prototypes,  licensing  U.S.  patents, evaluating  biometric  equipment  and
analyzing  the market conditions for the proprietary services and  products.
Consequently, the Company has incurred the expenses of start-up  and  patent
licensing.  Future operating results will depend on many factors,  including
the ability of the Company to raise adequate working capital, demand for the
Company's  services and products, the level of competition and the Company's
ability to satisfy governmental regulations and deliver company services and
products  while  maintaining quality and controlling  costs.  The  Company's
financial  statements have been prepared assuming the Company will  continue
as a going concern.

Results of Operations

     Period from January 1, 1999 to December 31, 1999

      The first years of existence for the Company achieved three main goals;
The  formation of the Company's organization to pursue its business strategy,
development of a production model and achieving the public company status  to
assist in funding the Company's objectives.

      Revenues.  The Company is a development stage enterprise as defined  in
Statement  of Financial Accounting Standards- No. 7, and has yet to  generate
any  revenues.  The  Company is devoting substantially  all  of  its  present
efforts  to: (1) developing its medical data management products and systems,
(2)  developing its market, and (3) obtaining sufficient capital to  commence
full operations.

      General  and  Administrative.  General and  administrative,  legal  and
consulting expenses for the year ended December 31, 1999 were $614,742  which
was  a increase over the $92,444 for the year ended December 31, 1998.   This
increase was primarily the result of increased expenses related to: (i) going
public,  and  (ii) common stock issued in lieu of cash payments to  employees
and consultants.

      Research  and  Development.  Research  and  Development  expenses  were
$281,438 for the year ended December 31, 1999.

      Net loss for the Company were $919,389 for the year ended December  31,
1999  as  compared  to net loss of $601,277 for the year ended  December  31,
1998.  This  increase  was  the  result of increasing  activity  and  related
additional expenses discussed above associated with being a development stage
enterprise.

Liquidity and Capital Resources

     The  receipt  of funds to the Company from Private Placement  Offerings
and  loans  obtained through private sources are anticipated to  offset  the
near term cash requirements of the Company. Since inception, the Company has
financed  its  cash  flow requirements through debt financing,  issuance  of
common  stock  for  cash  and services, and minimal cash  balances.  As  the
Company  expands its medical data management activities, it may continue  to
experience net negative cash flows from operations, pending receipt of sales
revenues,  and  will  be  required to obtain additional  financing  to  fund
operations through common stock offerings and bank borrowings to the  extent
necessary to provide its working capital.

     Over the next twelve months, the Company intends to develop its revenues
by  releasing its products under development to its target markets.  However,
the  Company  will  continue the research and development  of  its  products,
increase  the  number  of  its  employees, and expand  its  facilities  where
necessary  to meet product development and completion deadlines. The  Company
believes that existing capital and anticipated funds from operations will not
be  sufficient to sustain operations and planned expansion in the next twelve
months. Consequently, the Company will be required to seek additional capital
in  the future to fund growth and expansion through additional equity or debt

<PAGE>

financing  or credit facilities. No assurance can be made that such financing
would  be available, and if available it may take either the form of debt  or
equity.  In  either case, the financing could have a negative impact  on  the
financial condition of the Company and its Shareholders.

     Initial  financing  is  only to provide funds  to  prove  the  business
concept, to finish the development of the software, and to install the first
prototype system. Additional funds will be necessary to take the products to
market.  The  Company  hopes to enter into additional  funding  arrangements
through  strategic partnerships, merger, equity offering or  debt  offering.
Nothing has been secured as of this time.

     The Company anticipates that it will incur operating losses in the next
twelve months. The Company's lack of operating history makes predictions  of
future  operating  results difficult to ascertain. The  Company's  prospects
must  be  considered  in  light  of  the risks,  expenses  and  difficulties
frequently  encountered by companies in their early  stage  of  development,
particularly  companies in new and rapidly evolving  markets  such  as  bio-
medical.  Such  risks for the Company include, but are not  limited  to,  an
evolving  and unpredictable business model and the management of growth.  To
address these risks, the Company must, among other things, obtain a customer
base,   implement  and  successfully  execute  its  business  and  marketing
strategy,  continue  to  develop and upgrade its  technology  and  products,
provide  superior  customer  services  and  order  fulfillment,  respond  to
competitive  developments,  and  attract,  retain  and  motivate   qualified
personnel. There can be no assurance that the Company will be successful  in
addressing such risks, and the failure to do so can have a material  adverse
effect  on the Company's business prospects, financial condition and results
of operations.

Costs Associated with Year 2000 Problem

      The Company has incurred minimal expenses associated with the Year 2000
Problem.   As a result the Company being a Development Stage Enterprise,  the
Company's computer equipment is being purchased as Year 2000 compliant, where
possible.

ITEM 7.   FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

     See  Index  to  Financial Statements and Financial  Statement  Schedules
appearing on page F-1 through F-8 of this Form 10-KSB

ITEM 8.   CHANGES  IN  AND  DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING  AND
          FINANCIAL DISCLOSURE

     No Changes to Report

<PAGE>

PART III

ITEM 9.   DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT; COMPLIANCE WITH
          SECTION 16(a) OF THE EXCHANGE ACT.

     The following table sets forth the names, positions with the Company and
ages  of the executive officers and directors of the Company. Directors  will
be  elected at the Company's annual meeting of shareholders and serve for one
year  or until their successors are elected and qualify. Officers are elected
by  the Board and their terms of office are, except to the extent governed by
employment contract, at the discretion of the Board.
<TABLE>
            Name                Age                   Title
<S>                            <C>    <C>
James E. Beecham, MD             51    Chairman of the Board
William M. Somers, OD            53    Director
</TABLE>
Duties, Responsibilities and Experience

James  E.  Beecham, MD. Founded Anonymous Data Corporation and as served  as
Chairman  of  the Board since inception in November of 1996.  From  1990  to
present  Dr. Beecham has been a Physician/Pathologist at Laboratory Medicine
Consultants  Laboratories,  Inc. Dr. Beecham served  as  Vice  President  of
Laboratory  Medicine Consultants Laboratories, Inc., a full service  medical
laboratory located in Las Vegas, Nevada from its inception until  it's  sale
in  1997. Dr. Beecham is a member of the Board of Directors and full partner
in  Laboratory Medicine Consultants, Ltd., a medical practice consisting  of
12  pathologists  located  in Las Vegas, Nevada. Dr.  Beecham  received  his
medical degree from the University of Florida School of Medicine in 1973. He
has  been engaged in the full time practice of medicine in the specialty  of
Pathology  since  his completion of a residency at the University  of  North
Carolina   and  University  of  Washington  in  1978.  Dr.  Beecham   spends
approximately 25% of his time on ADC related activities.

William  M.  Somers, OD has served as Director of Anonymous Data  Corporation
since  November, 1998. From 1994 until present William Somers,  a  Doctor  of
Optometry has maintained a full time optometry practice in Las Vegas, Nevada.
He  has held numerous committee positions throughout his career including the
Medicare  Carrier  Advisory Committee, the Nevada  chapter  of  the  American
Optometric Association and advisory board committee member and spokesman  for
Vistakon (Johnson & Johnson contact lenses). He received his optometry degree
from the Southern California College of Optometry.

LIMITATION OF LIABILITY OF DIRECTORS

     Pursuant  to  the  Nevada  General  Corporation  Law,  our  Articles  of
Incorporation  exclude  personal liability for  our  Directors  for  monetary
damages  based  upon  any violation of their fiduciary duties  as  Directors,
except  as  to  liability  for any breach of the duty  of  loyalty,  acts  or
omissions  not  in good faith or which involve intentional  misconduct  or  a
knowing  violation of law, or any transaction from which a Director  receives
an  improper personal benefit. This exclusion of liability does not limit any
right  which  a Director may have to be indemnified and does not  affect  any
Director's  liability under federal or applicable state securities  laws.  We
have  agreed  to  indemnify  our directors against expenses,  judgments,  and
amounts paid in settlement in connection with any claim against a Director if
he  acted  in  good  faith and in a manner he believed  to  be  in  our  best
interests.

BOARD OF DIRECTORS COMMITTEES AND COMPENSATION

Compensation Committee Interlocks and Insider Participation

     The  Board  of Directors does not have a Compensation Committee.   James
Beecham, President, oversaw the compensation of our executive officers.
<PAGE>

Board of  Director's Report on Executive Compensation

     General.   As  noted  above,  our Board of Directors  does  not  have  a
Compensation  Committee  and,  accordingly,  during  the  fiscal  year  ended
December  31,  1999, the Board of Directors, through the President,  reviewed
and approved the compensation of our executive officers.

     Overall   Policy;   Significant  Factors.   During  fiscal   1999,   the
compensation  decisions  made by the Board of Directors  in  respect  of  our
executive orders were influenced by three major factors.  First, our start-up
nature  brings  with  it  all of the normal capital requirements  to  sustain
growth, therefore certain stock compensation was granted in lieu of salaries,
commissions  and for services rendered.  This practice may be  extended  into
the  future on a case by case basis and accordingly filed with the Securities
and  Exchange  Commission.   Finally,  as  we  continue  to  mature,  certain
additions  to  the executive staff will be required.  As we are  required  to
seek  talent  in outside market, we will be required to provide a competitive
compensation package.

     As  overall  policy, however, the Board continues to believe that  long-
term compensation tied to the creation of stockholder value should constitute
a  significant  component of the compensation to be earned by  our  executive
officers.   In  this  respect, it will be the Board's policy  to  attempt  to
restrain  base  cash compensation (subject to competitive  pressures),  while
providing  the  incentive  for Management to increase  stockholder  value  by
providing  such officers with significant numbers of market-price stock  that
will  not confer value upon the officers unless and until the Company's share
price  rises.   The  Board  of  Directors expects  that  stock  options  will
constitute  a significant component of the compensation package  provided  to
executive officers.

     The  Board  believes that cash bonuses are, at times, appropriate  based
upon  the  performance  of the Company's business compared  to  our  internal
expectations and general business conditions.

ITEM 10.  EXECUTIVE COMPENSATION

The  following  table  sets  forth the cash  compensation  of  the  Company's
executive  officers  and  directors during each of  the  fiscal  years  since
inception  of the Company. The remuneration described in the table  does  not
include  the cost to the Company of benefits furnished to the named executive
officers, including premiums for health insurance and other benefits provided
to  such individual that are extended in connection with the conduct  of  the
Company's   business.  The  value  of  such  benefits  cannot  be   precisely
determined,  but  the executive officers named below did  not  receive  other
compensation in excess of the lesser of $50,000 or 10% of such officer's cash
compensation.
<TABLE>
Summary Compensation Table
                                                             Long Term
                            Annual Compensation            Compensation
                                                        Restricted
Name and Principal                        Other Annual    Stock
Position             Year  Salary  Bonus  Compensation    (2)(3)    Options
<S>                  <C>   <C>     <C>    <C>           <C>        <C>
James E. Beecham(1)  1996      -0-  -0-       -0-          -0-        -0-
James E. Beecham     1997      -0-  -0-       -0-          -0-        -0-
James E. Beecham     1998      -0-  -0-       -0-          -0-        -0-
James E. Beecham     1999      -0-  -0-       -0-              -0-    -0-
William M. Somers    1998      -0-  -0-       -0-           $1,000    -0-
William M. Somers    1999      -0-  -0-       -0-           $9,000    -0-
</TABLE>
(1)   Beecham purchase 6,000,000 shares of restricted stock in the Company at
  $.02  per  share as the result of his Pre-Incorporation Agreement with  the
  Company.
<PAGE>


Compensation of Directors

   All  directors will be reimbursed for expenses incurred in attending Board
   or committee meetings.

Stock Option Plan

     The  following descriptions apply to stock option plan which the Company
has adopted; however, no options have been granted as of this date.

     The  Company reserved for issuance an aggregate of 1,500,000  shares  of
common  stock  under a Stock Option Plan (the "Stock Option Plan")  and  Non-
Employee  Directors' Plan described below (the "Directors' Plan")  which  has
been adopted by the Company.  These plan are intended to encourage directors,
officers,  employees and consultants of the Company to acquire  ownership  of
common  stock.   The  opportunity  so  provided  is  intended  to  foster  in
participants a strong incentive to put forth maximum effort for the continued
success  and growth of the Company, to aid in retaining individuals  who  put
forth   such  efforts,  and  to  assist  in  attracting  the  best  available
individuals to the Company in the future.

     Officers (including officers who are members of the Board of Directors),
directors (other than members of the Stock Option Committee (the "Committee")
to  be  established  to administer the Stock Option Plan and  the  Directors'
Plan) and other employees and consultants of the Company and its subsidiaries
(if  established) will be eligible to receive options under the planned Stock
Option  Plan.  The Committee will administer the Stock Option Plan  and  will
determine  those  persons  to whom options will be  granted,  the  number  of
options  to be granted, the provisions applicable to each grant and the  time
periods during which the options may be exercised.  No options may be granted
more than ten years after the date of the adoption of the Stock Option Plan.

     Unless  the  Committee,  in its discretion, determines  otherwise,  non-
qualified  stock options will be granted with an option price  equal  to  the
fair  market  value of the shares of common stock to which the  non-qualified
stock  option relates on the date of grant.  In no event may the option price
with respect to an incentive stock option granted under the Stock Option Plan
be  less  than  the  fair  market value of such common  stock  to  which  the
incentive  stock  option relates on the date the incentive  stock  option  is
granted.

     Each option granted under the Stock Option Plan will be exercisable  for
a  term  of  not more than ten years after the date of grant.  Certain  other
restrictions will apply in connection with this Plan as to when  some  awards
may  be  exercised.  In the event of a change of control (as defined  in  the
Stock Option Plan), the date on which all options outstanding under the Stock
Option  Plan  may  first  be exercised will be accelerated.   Generally,  all
options terminate 90 days after a change of control.

<PAGE>

ITEM 11.  SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

Security Ownership of Certain Beneficial Owners.

      The  following table sets forth certain information as of December  31,
1999  with  respect to the beneficial ownership of common stock by  (i)  each
person  who  to the knowledge of the Company, beneficially owned or  had  the
right  to  acquire more than 10% of the Outstanding common stock,  (ii)  each
director of the Company and (iii) all executive offices and directors of  the
Company as a group.

<TABLE>

        Name of Beneficial Owner (1)             Number         Percent
                                               of Shares      Of Class (2)
<S>                                           <C>            <C>
James E. Beecham, MD                             5,100,000               54%
William M. Somers, OD                               10,000                0%
All Directors & Officers as a Group              5,110,000               54%
</TABLE>
(1)  As  used in this table, "beneficial ownership" means the sole or  shared
    power to vote, or to direct the voting of, a security, or the sole or shared
    investment power with respect to a security (i.e., the power to dispose of,
    or to direct the disposition of, a security).  In addition, for purposes of
    this  table,  a  person is deemed, as of any date, to  have  "beneficial
    ownership" of any security that such person has the right to acquire within
    60 days after such date.
(2)  Figures are rounded to the nearest percentage. Less than 1% is reflected
     as 0%.

ITEM 12.  CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

PreIncorporation  Agreement.  On  the 1st of  November,  1996,  the  Company
entered into an agreement with James Beecham, MD, wherein Beecham agreed  to
provide  exclusively to the Company an option to enter into a formal License
Agreement. The Pre-Incorporation Agreement provided that James Beecham would
receive 6,000,000 shares of common stock at a price to Beecham of $0.02  per
share  to be paid over two years. The agreement recited that the option  was
the only asset of the to be formed corporation.

License  Agreement. On May 14 1998, the Company entered into  an  "Exclusive
Licensee  Territorial Agreement" for two U.S. patents  relating  to  medical
biometrics with Dr. James Beecham, Chairman of the Company, in exchange  for
future  royalties  in  the amount of three percent (3%)  of  the  first  $10
million  gross revenues to the Company from the manufacture,  use,  sale  or
operation  of the Products and Services, two percent (2%) of gross  revenues
which  exceed $10 million but are under $25 million and one percent (1%)  of
gross  revenues  which  exceed $25 million. A disinterested  Company  senior
management  official approved the agreement which was then ratified  by  the
Board  of  Directors.  The  Company believes the agreement  is  commercially
reasonable and generally equivalent to what a third party would receive with
no affiliation.

Officer Loans.  In November 1999, the Chairman loaned the Company $51,000  at
10%  annually.  Interest payments are due annually with principal balance due
in 2004.

<PAGE>

ITEM  13. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND  REPORTS ON FORM 8-K

(a)  Documents filed as part of this Report

     1.   Financial Statements:

     A.   INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

     1.     Independent Auditors  Report                           F-1
     2.     Financial Statements:
          Balance Sheet                                            F-2
          Statement of Operation                                   F-3
          Statement of Changes in Stockholders'                    F-4
          Statement of Cash Flows                                  F-5
          Notes to Consolidated Financial Statements         F-6 - F-7

                All schedules are omitted because they are not applicable  or
          the  required  information is shown in the  consolidated  financial
          statements or notes thereto.

        2.   During the fiscal year 1999, the Company filed the following  8-Ks.
             8-K filed November 4, 1999
             8-K filed November 11, 1999

          3.   Subsequent to the end of the fiscal year, the Company filed the
               following reports on Form 8-K
               8-K filed February 1, 2000
<PAGE>

                                 SIGNATURES

      Pursuant  to the requirements of Section 13 or 15(d) of the  Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed
on our behalf by the undersigned, thereunto duly authorized.

ANONYMOUS DATA CORPORATION                   DATED: April 16, 2000



By:/s/ James Beecham
     James Beecham
     President


      Pursuant  to the requirements of the Securities Exchange Act  of  1934,
this  report has been signed below by the following persons on behalf of  the
registrant and in the capacities and on the dates indicated.

Signature                     Title                         Date

/s/ James Beecham             President           April 17, 2000
James Beecham

/s/ William Somers            Director            April 17, 2000
William Somers
<PAGE>
                        INDEPENDENT AUDITORS' REPORT



Board of Directors
Anonymous Data Corporation
Las Vegas, Nevada

We   have  audited  the  balance  sheet  of  Anonymous  Data  Corporation  (a
development  stage  enterprise) as of December  31,  1999,  and  the  related
statements  of operations, stockholders' equity and cash flows  for  the  two
years  ended  December 31, 1998 and 1999, and for the period  from  inception
(November 15, 1996) to December 31, 1997. These financial statements are  the
responsibility of the Company's management. Our responsibility is to  express
an opinion on these financial statements based on our audit.

We  conducted  our  audits  in  accordance with generally  accepted  auditing
standards.  Those standards require that we plan and perform  the  audits  to
obtain  reasonable assurance about whether the financial statements are  free
of  material  misstatement.  An audit includes examining, on  a  test  basis,
evidence  supporting the amounts and disclosures in the financial statements.
An   audit  also  includes  assessing  the  accounting  principles  used  and
significant  estimates made by management, as well as evaluating the  overall
financial  statement  presentation.  We believe that  our  audits  provide  a
reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in
all  material respects, the financial position of Anonymous Data  Corporation
as  of December 31, 1999, its results of development stage operations and its
cash  flows  for the periods presented in conformity with generally  accepted
accounting principles.

The  accompanying balance sheet has been prepared assuming that  the  Company
will  continue  as  a  going concern.  As discussed in Notes  1  and  3,  the
Company's  ability  to  commence operations and realize  its  investments  in
assets is dependent upon obtaining additional sources of capital to fund  the
successful completion of its equipment and software development and marketing
of its products.  This condition raises substantial doubt as to the Company's
ability to continue as a going concern.  Management's plans in regard to this
matter  are described in Note 3. The financial statements do not include  any
adjustments that might result from the outcome of this uncertainty.






March 27, 2000

<PAGE>
<TABLE>
ANONYMOUS DATA CORPORATION
(A Development Stage Enterprise)
BALANCE SHEET
December 31, 1999


ASSETS
<S>                                                          <C>
Current assets, cash                                               $ 3,939

Equipment and software, less accumulated
depreciation of $36,224                                             89,225

Unamortized patent costs                                            96,038
                                                               -----------
                                                                 $ 189,202
                                                                ==========
LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
Accounts payable                                                  $ 37,569
Accrued taxes                                                        7,089
Accrued interest, officer/director                                   5,100
Capitalized lease obligation                                         1,528
                                                                 ---------
                                                                    51,286
Long-term debt, officer/director                                    51,000
                                                                 ---------
                                                                   102,286
                                                                 ---------
Stockholder's equity:

Common stock, $.001 par, 100,000,000
shares authorized, 9,438,160 shares
issued and outstanding

Preferred stock, $.001 par, 25,000,000
shares authorized, none issued and
outstanding                                                          9,438

Additional paid-in capital                                       1,692,376

Deficit accumulated during development stage                   (1,614,898)
                                                               -----------
                                                                    86,916
                                                               -----------
                                                                 $ 189,202
</TABLE>
                                                               ===========
                    See notes to financial statements
<PAGE>
<TABLE>
ANONYMOUS DATA CORPORATION
(A Development Stage Enterprise)
STATEMENT OF OPERATIONS




                                                                 From
                                        Year Ended December  Inception to
                                                31,          December 31,
                                         1999        1998        1997
<S>                                    <C>         <C>       <C>
Operating costs and expenses:
Research and development                $ 281,438  $ 496,468      $ 33,366
Administrative                            614,742     92,444        59,116
Depreciation                               26,462      8,012         1,750
Interest                                    5,785      4,353
                                       ----------  ---------   -----------
                                          928,427    601,277        94,232
                                       ----------   --------   -----------
Income:
Interest                                    2,109
Other                                       6,929
                                       ----------
                                            9,038
                                       ----------
Net loss                                $ 919,389  $ 601,277      $ 94,232
                                       ==========  =========   ===========
Loss per share                            $ 0.099    $ 0.076       $ 0.012
                                       ==========  =========   ===========
Weighed average number of shares
outstanding                             9,325,932  7,936,165     7,591,250
                                       ==========  =========   ===========
</TABLE>
                    See notes to financial statements
<PAGE>
<TABLE>
ANONYMOUS DATA CORPORATION
(A Development Stage Enterprise)
STATEMENT OF SHAREHOLDER'S EQUITY
FOR THE YEARS ENDED DECEMBER 31,1999 AND 1998 AND FOR THE PERIOD FROM
INCEPTION (NOVEMBER 15,1996) TO DECEMBER 31,1997



                                              Stock      Deficit
                   Common Stock             Subscrip-  accumulated
                                  Additional  tion       during
                                   Paid-in   Receiv-   development
                                   capital    able        stage      Total
                            Par
                  Shares   Value
<S>               <C>      <C>   <C>        <C>        <C>          <C>
Common shares
issued from
inception
(November
15,1996) to:
Officer with
stock
subscription
receivable      6,000,000  $6,000  $114,000  (120,000)                    $-

Officer/directo
r for expense
reimbursement   1,000,000  $1,000   $19,000                          20,000
Employees for
services          235,000     235     4,465                           4,700
Employees for
cash              175,000     175     3,325                           3,500
Consultants for
services          325,000     325     6,175                           6,500
Payment of
stock
subscription
receivable
from founding
shareholder                                    83,164                83,164
Net loss                                                  (94,232) (94,232)
                ---------  ------  --------  -------- ------------ --------
Balances,
December 31,
1997            7,735,000   7,735   146,965  (36,836)     (94,232)   23,632

Common shares
issued in 1998
to:
Officer/directo
r for expense
reimbursement      73,000      73    74,581                          74,654
Officers and
directors for
services          201,000     201   200,799                         201,000
Employees for
services           18,500      19    18,481                          18,500
Consultants for
services          373,200     373   372,827                         373,200
Others for cash
                   93,300      93    93,207                          93,300
Payment of
stock
subscription
receivable                                     36,836                36,836
Net loss                                                 (601,277) (601,277
                                                                          )
                ---------  ------   -------   ------- ------------ --------
Balances,
December 31,
1998            8,494,000   8,494   906,860              (695,509)  219,845

Common shares
issued in 1999
to:
Officers and
directors for
services          134,500     135   134,365                         134,500
Consultants for
services          266,710     266   286,444                         286,710
Others for cash
                  542,950     543   542,407                         542,950
Less offering
costs                             (177,700)                        (177,700
                                                                          )
Net loss                                                 (919,389) (919,389
                                                                          )
                ---------  ------ ---------   ------- ------------ --------
Balances,
December 31,
1999            9,438,160  $9,438 1,692,376        $- $(1,614,898)  $86,916
                =========  ====== =========   ======= ============ ========
</TABLE>
                     See notes to financial statements
<PAGE>
<TABLE>
ANONYMOUS DATA CORPORATION
(A Development Stage Enterprise)
STATEMENT OF CASH FLOWS

                                                                  From
                                                                Inception
                                                                   to
                                                                December
                                             Year Ended            31,
                                          1999        1998        1997
<S>                                  <C>          <C>          <C>
Operating activities:
Net loss                              $ (919,389)  $ (601,277)  $ (94,232)
Depreciation                               26,462        8,012       1,750
Expenses reimbursed with stock            401,210      483,354      31,200
Change in operating assets:
Decrease in prepaid expenses                1,000      (1,000)
Change in operating liabilities:
Increase in accounts payable               31,699        7,319
Increase in accrued expenses                5,640
Increase in accrued interest                5,100
                                      -----------   ----------  ----------
Net cash used by operating
activities                              (448,278)    (103,592)    (61,282)
                                      -----------   ----------  ----------
                                                                         -
Investing activities:
Purchase of equipment                   (102,708)      (8,746)     (8,749)
Patent costs                             (35,400)     (52,090)     (8,548)
                                      -----------   ----------  ----------
Net cash used in investing
activities                              (138,108)     (60,836)    (17,297)
                                      -----------   ----------  ----------
Financing activities:
Payment by founding shareholder
of stock subscription receivable                        36,836      83,164
Payments on lease purchase obligation
                                          (3,718)
Sale of common stock                      542,950       93,300       3,500
Offering costs paid with cash            (13,700)     (10,000)
Advances from founding shareholder
for stock                                               50,000
Loan from founding shareholder             51,000
                                       ----------   ----------  ----------
Net cash provided by financing
activities                                576,532      170,136      86,664
                                       ----------   ----------  ----------
Net increase (decrease) in cash           (9,854)        5,708       8,085
Cash, beginning                            13,793        8,085           -
                                       ----------   ----------  ----------
Cash, ending                              $ 3,939     $ 13,793     $ 8,085
                                       ==========   ==========  ==========
Non-cash financing and investing
activities:
Exchange of stock for offering costs     $ 20,000    $ 134,000
                                       ==========    =========
Equipment purchased through lease
purchase obligation                                    $ 5,246
                                                   ===========
Settlement of shareholder advances
with stock                                            $ 50,000
                                                    ==========
</TABLE>
                    See notes to financial statements
<PAGE>

ANONYMOUS DATA CORPORATION
(A Development Stage Enterprise)
NOTES TO FINANCIAL STATEMENTS

1.   Summary of significant accounting policies:

Nature  of  business.   The Company is a development  stage  enterprise  and,
therefore,  as  of December 31, 1999, has not commenced business  operations.
The Company was incorporated in 1996, for the purpose of developing biometric
equipment  and  related  software  to store  and  retrieve  data  of  medical
laboratory testing. The Company is in the research and development  phase  of
testing   its  technical  equipment  and  software.   The  Company's   future
operations  could  be  affected  by adverse changes  in  local  and  national
economic conditions.  (See Note 3.)

Offering costs.  The Company has offered its unregistered common stock to the
public  in offerings intended to be exempt from registration with the  United
States  Securities  and  Exchange  Commission  (SEC)  pursuant  to  Rule  504
promulgated under the Securities Act of 1933. The costs of the offerings have
been offset against the proceeds to date.

Use  of  estimates.  Timely preparation of financial statements in conformity
with  generally  accepted accounting principles requires management  to  make
estimates and assumptions that affect reported amounts and disclosures,  some
of which may require revision in future periods.

Equipment,  depreciation  and  amortization. Equipment  is  stated  at  cost.
Depreciation and amortization is provided by an accelerated method  over  the
estimated useful live of the assets.

Stock  compensation  awards.   The Company has adopted  Financial  Accounting
Standard Board Statement No. 123 Accounting for Stock-Based Compensation, for
valuing compensatory stock and option awards. (See Note 6.)

Patent costs.   Cost associated with patents and patents pending are deferred
and  amortized  based on the lives of patents granted.  In the  event  patent
applications  are  denied  or abandoned, such costs  are  written  off.   For
patents granted late in the year, amortization begins in the following year.

Advertising costs.   Advertising costs are expensed when incurred and totaled
$57,546 and $22,693 for 1999 and 1998.

Loss  per  share.   Loss per share is computed based on the weighted  average
number of shares outstanding for the periods presented.

2.Related party transactions:

In  May  1998,  Dr. James E. Beecham (Chairman of the Board of Directors  and
majority  shareholder and president of the Company) licensed to  the  Company
the  rights  associated  with  two U.S. patents  pending.  The  licenses  are
irrevocable  until May 14, 2008. Dr. Beecham has also agreed  to  extend  the
licenses  for  an  additional  eight years depending  upon  performance.   In
consideration  for  the  assignment of rights, Dr.  Beecham  will  receive  a
royalty of 3% of the first $10 million, 2% of $10 to $25 million, and  1%  in
excess  of $25 million in gross revenues to the Company from the manufacture,
use, sale or operation of the products and services.

In  December  1998, the Company signed a consultant agreement  with  Protocol
Services, A.V.V. providing for payment to the consultant of 10% of the  gross
proceeds from any sales or business generated by the consultant. The  Company
issued  50,000  shares  of  restricted stock valued  at  $1  per  share.   An
additional 25,000 shares are to be issued under terms of the agreement  at  a
value  to be determined.  The length of the contract is interminable but  may
be terminated at any time by the Company for just cause.

In  November  1999, the Chairman loaned the Company $51,000  dollars  at  10%
annually.  Interest payments are due annually with principal balance  due  in
its entirety in 2004.

During  early 1999, the Company issued 129,500 shares of its common stock  to
its officers/directors valued at $1 per share as compensation.
<PAGE>

3. Going concern contingency:

The  Company's ability to complete certain research projects and  development
of  its  equipment  and  software development  is  dependent  upon  obtaining
additional equity or debt financing. This condition could prevent the Company
from  commencing business operations and continuing as a going concern.   The
balance  sheet, however, has been prepared assuming the Company will continue
as a going concern, and it reflects no adjustments that might result from the
outcome of this uncertainty. However, because of this uncertainty, no  effect
has  been given in the balance sheet to any future income tax benefit of  the
loss  recorded  to date.  The Company has a net operating loss carry  forward
expiring  in year 2019 available to reduce future income tax expense  in  the
amount of approximately $1,600,000.

Management expects to raise additional equity capital by offering its  common
stock for sale to investors through private placement or by registration with
the SEC under the Securities Act of 1933 or obtain debt financing to complete
its  research  projects  and  equipment and  obtain  the  related  additional
patents.  Management  expects  that  the Company's  medical  data  management
equipment, when completed, will have a wide range of applications in  medical
testing  data  storage.   Management's ability to effectively  implement  its
plans  could have a material and adverse effect upon the Company's  business,
financial condition and future operations.

5.                     Lease commitment:

The Company leases office space under a term expiring December 31, 2000, with
an  option  to  renew for an additional three years.  Future  annual  minimum
lease payments are $16,150.

6.                     Stock option plan:

The  Company  adopted  a  stock option plan which reserves  for  issuance  an
aggregate of 1,500,000 shares of common stock.  No options have been  granted
to date.

7.                     Subsequent event:

Subsequent  to  December 31, 1999, the Company issued 700,000  and  1,020,000
shares  of common stock to consultants for services registered with  the  SEC
through the filing of Forms S-8 on January 26, and March 24, 2000, at  market
values  ranging  between $1.27 and $1.64 per share.   The  Company  has  also
issued 372,500 shares under Rule 144 restricted common shares for services at
market values ranging between $1.47 and $2.26 per share.